These innovative compounds represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://monicalytj026238.creacionblog.com/38996539/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide